7 recent reports on hepatology
Click Here to Manage Email Alerts
Healio Gastroenterology presents the following reports on the most recent research on hepatology.
These reports include new research on nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and cirrhosis.
Standard of care lifestyle counseling improves NASH, fibrosis in children with NAFLD
Standard of care lifestyle counseling correlated with improvements in nonalcoholic steatohepatitis or fibrosis in half of the children with nonalcoholic fatty liver, according to study results published in Gastroenterology.
However, investigators observed continual progression in more than one-third of children within 2 years. READ MORE
Q&A: Perspectum to evaluate imaging device as tool to identify NASH patients
Perspectum announced it will evaluate the use of LiverMultiScan as a diagnostic tool to identify eligible patients for enrollment into nonalcoholic steatohepatitis clinical trials.
The Virginia Commonwealth University, University of Virginia, Mount Sinai, and Liver Centers of Texas will collaborate in conducting the Non-Invasive Quantification of Liver Health in NASH (N-QUAN) trial as part of the evaluation. This prospective trial will include 225 patients with suspected NASH. READ MORE
FDA recommends approval of terlipressin for treatment of HRS-1 despite concerns
FDA Cardiovascular and Renal Drugs Advisory Committee voted 8-7 to recommend approval of terlipressin for the treatment of hepatorenal syndrome type 1 in patients with cirrhosis.
Terlipressin, developed by Mallinckrodt plc, is an investigational agent that consists of a synthetic, 12-amino-acid peptide analog of vasopressin. READ MORE
Physical activity linked with lower mortality in NAFLD
Objectively measured physical activity was associated with lower all-cause mortality in patients with nonalcoholic fatty liver disease, according to research published in Clinical Gastroenterology and Hepatology.
Donghee Kim, MD, PhD, of the division of gastroenterology and hepatology at Stanford University School of Medicine, and colleagues wrote that cardiovascular disease is the leading cause of mortality in patients with NAFLD due to the disease’s bidirectional association with metabolic syndrome. READ MORE
Patients with cirrhosis plus COVID-19 have higher mortality rates
Patients with cirrhosis and COVID-19 had higher mortality rates than patients with COVID-19 alone, but similar rates as patients with just cirrhosis, according to research published in Gut.
Jasmohan Bajaj, MD, from Virginia Commonwealth University, and colleagues wrote that patients with cirrhosis are assumed to be high-risk in the setting of COVID-19 due to immune dysfunction and altered gut-liver axis, but data are currently lacking. READ MORE
FMT effective for CDI in patients with cirrhosis
Fecal microbiota transplantation was safe and effective for the treatment of Clostridioides difficile infection in patients with cirrhosis, according to study results.
Monika Fischer, MD, of the division of gastroenterology at Indiana University School of Medicine, and colleagues wrote that patients with cirrhosis are at higher risk for CDI due to dysbiosis, functional immunosuppression and frequent use of antibiotic therapies. However, the FMT working group has recommended against FMT for this population due to the potential for adverse events. READ MORE
Lanifibranor meets efficacy, safety endpoints in phase 2b NASH trial
Inventiva announced lanifibranor met primary and secondary endpoints in a phase 2b study for treatment of nonalcoholic steatohepatitis, according to speaker at an Inventiva web conference.
“Lanifibranor (1,200 mg) met the primary endpoints with a statistically significant reduction, after 6 months of treatment, of the Steatosis Activity Fibrosis score, which combines assessments of hepatocellular inflammation and ballooning, with no worsening in intention to treat and per protocol populations,” Pierre Broqua, PhD, chief scientific officer and cofounder of Inventiva, said during his presentation. READ MORE
Collapse
Read more about
Click Here to Manage Email Alerts